Table 2 Comparison of clinical and laboratory variables of amayloidosis.
| Â | Monsoury et al8 (with ASFA) | Wakhlu et al 9 (with ASFA) | Gomez-Casanovas et al7 (with SFA) | Alishiri et al (with ASFB) |
|---|---|---|---|---|
No. of patients | 112 | 113 | 313 | 220 |
Positive for amyloid no (%) | 8(7) | 30(26.5) | 51(16%) | 15(6.8) |
Subclinical amyloid (%) | 62.5 | 73.3 | 67 | 46.6 |
Fat deposit analysis no | 8 | 30 | 51 | 15 |
   1+ | 7 | 23 | 12 | 13 |
   2+ | 1 | 5 | 19 | 2 |
   3+ | 0 | 2 | 20 | 0 |
Duration of disease (year) | >5 | >5 | >5 | >5 |
Age, yrs, mean ± SD | 54(41–65) | 46 ± 8.7 | 61.4 ± 13.7 | 55.2 ± 12 |
Male: female | 0:8 | 8:22 | 1:19 | 1:3 |
Disease duration, years mean ± SD | 17(12–25) | 10 ± (5–22) | 16.8 ± 10.5 | 9.13 ± 4.67(5–20) |
Age at disease onset, years ± SD | 32.5 (22–50) | 36 ± 10 | 44.9 ± 14.4 | 46.07 (27–65) |
Follow up. Mo, mean ± SD | - | 48 ± 36(12–14) | 69.7 ± 53.3 | 12 |
RF positive, no. (%) | - | 25(83.3) | 45(75) | 10(66.6) |
Proteinuria, no (%) | 2(25) | 7(23.3) | 8(13) | 8(53.3) |